Keyphrases
Acute Myeloid Leukemia
100%
Older Patients
58%
Pharmacoeconomics
50%
Pharmacology
50%
Oncohematology
50%
Frailty Assessment
50%
Treatment Opportunity
50%
Oncogeriatrics
50%
Treatment Policy
50%
Population Analysis
50%
Treatment Outcome
50%
Combination Regimen
37%
Novel Regimens
25%
Adverse Events
25%
Venetoclax
20%
Intensive Chemotherapy
20%
Newly Diagnosed
16%
Phase II Clinical Trial
12%
Pre-existing Comorbidity
12%
Care Pathway
12%
Targeted Chemotherapy
12%
Remission Rate
12%
Baseline Health
12%
Clinical Trials
12%
Phase III Clinical Trial
12%
Maximum Benefit
12%
Ongoing Clinical Trials
12%
Frailty
12%
Oncologists
12%
Geriatrician
12%
New Agents
12%
Chemotherapy Drugs
12%
Response Rate
12%
Time-dependent Toxicity
12%
Novel Combinations
12%
Health Care Costs
12%
Overall Survival
12%
Narrative Review
12%
Azacitidine
12%
Treatment Intensity
12%
Health Status
12%
Quality of Life
12%
Treatment Line
12%
National Treatment Guidelines
12%
Population-based Retrospective Cohort Study
8%
Median Overall Survival
8%
Difficult-to-treat
8%
Friesland
8%
European LeukemiaNet
8%
Bone Marrow
8%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Frailty
50%
Clinical Trial
37%
Adverse Event
25%
Overall Survival
20%
Venetoclax
20%
Health Status
12%
Azacitidine
12%
Geriatrician
12%
Oncologist
12%
Quality of Life
12%
Spontaneous Remission
12%
Side Effect
12%
Health Care Cost
12%
Leukemia
8%
Cancer
8%
Hypomethylating Agent
8%
Stem Cell Therapy
8%
Retrospective Cohort Study
8%